If you are suffering from Cystic Fibrosis then its time to keep all stress behind since The Cystic Fibrosis Foundation and Vertex Pharmaceuticals of Cambridge, Mass. have recently made a public announcement that a new drug has been invented which can heal the primary cause of cystic fibrosis.
But what is Cystic Fibrosis?
A study reveals nearly 30,000 people in the United States suffer from Cystic Fibrosis, which occurs due to a genetic mutation that forms an upsurge of thick mucus in the lungs as well as the digestive system. It causes acute lung infections and severe damage to the body’s capacity of digesting food.
It is observed that people with CF seldom survive after their mid-30′s. The existing drugs can only treat symptoms of the ailment, while the new medicine which has been trialed on few patients can target the defective protein that sources the malady.
The patients whom the trail has been conducted upon are experiencing remarkable progress in lung function and weight gain. When our reporter spoke to one of them named Emily she replied, “My breathing problem has been improved a lot after going through the prescribed medication. I knew it was a trial and anything can happen in between. But fortunately everything came out just wonderful offering a new ray of hope.”
Role of the VX-770 to cure Cystic Fibrosis
The drug VX-770 targets straight to the defective protein. VX-770 is at present being experimented together with another drug VX-809 in patients having two copies of Delta F508 mutation. VX-770 helps “open the gate” at the cell surface which enables the protein to flow through, as it happens in healthy cells. As a result the restoration of proper flows of salt and fluids on the surface of the lung becomes smoother.
Vertex announced the company shall apply for U.S approval of the drug during the second half of the year. Industry experts have shown an estimate that if VX-770 gets the U.S approval then it can earn an annual revenue of some $600 million.
